◀ Back to TP53

HLA-DRB1 — TP53

Text-mined interactions from Literome

Wu et al., Oncogene 1999 : Our results suggest that the p53 dependent transcriptional induction of KILLER/DR5 death receptor is restricted to cells undergoing apoptosis and not cells undergoing exclusively p53 dependent G1 arrest
Sheikh et al., Leukemia 2000 : Recent evidence suggests that p53 upregulates the expression of death receptors Fas and DR5 , and thus, may mediate apoptosis in part via Fas and/or DR5
Kim et al., Int J Oncol 2001 (Colonic Neoplasms...) : The results reveal that Ad-p53 induces the TRAIL receptor KILLER/DR5 and, like radiation or chemotherapy may effectively reverse TRAIL resistance
Yoshida et al., FEBS Lett 2001 : The expression of DR5 is up-regulated at the transcriptional level by p53 , genotoxic stress and so on
Wagner et al., Cancer Biol Ther 2003 (Lymphoma, Follicular) : In chemosensitive FL cells, we found that DNA damaging drugs promote apoptosis through p53 dependent upregulation of the TRAIL-DR5 receptor, resulting in activation of caspase-8 and downstream executioner caspases, thereby evading bcl-2 mediated suppression of apoptosis
Wang et al., Proc Natl Acad Sci U S A 2003 (Carcinoma...) : Our studies elucidate a mechanism for restoration of TRAIL sensitivity in MMR-deficient Bax-/- human cancers through p53 dependent activation of KILLER/DR5 and reconstitution of a type I death pathway
Bedi et al., Apoptosis 1998 : The other demonstrates p53 mediated induction of DR5 , a death receptor of the tumour necrosis factor receptor family, that induces death by caspase mediated proteolysis
Liu et al., Cancer Res 2004 (Breast Neoplasms) : In the present study, we have demonstrated that DR4 is a p53 target gene and is regulated by p53 through a functional intronic p53 binding site (p53BS) based on the following lines of evidence : ( a ) the p53BS in the DR4 gene is almost identical to the one found in the first intron of the DR5 gene in terms of their locations and sequences ; ( b ) DR4 p53BS bound to p53 protein in intact cells upon p53 activation as demonstrated by a chromatin immunoprecipitation assay ; ( c ) a luciferase reporter vector carrying the DR4 p53BS upstream of an SV40 promoter exhibited enhanced luciferase activity when transiently cotransfected with a wild-type p53 expression vector in p53-null cell lines or stimulated with DNA damaging agents in a cell line having wild-type p53 ; and ( d ) when the DR4 p53BS, together with its own corresponding promoter region in the same orientation as it sits in its natural genomic locus, was cloned into a basic luciferase vector without a promoter element, its transcriptional activity was strikingly increased by cotransfection of a wild-type p53 expression vector or treatment with DNA damaging agents ... Thus, we conclude that p53 directly regulates the expression of the DR4 gene via the novel intronic p53BS
Tomasetti et al., FEBS Lett 2006 (Neoplasms) : We show that alpha-TOS activates expression of DR4/DR5 in a p53 dependent manner and re-establishes sensitivity of resistant MM cells to TRAIL mediated apoptosis, as documented in p53wt MM cells but not in their p53null counterparts
Carter et al., Blood 2008 (Leukemia, Myeloid, Acute) : Triptolide sensitizes AML cells to TRAIL induced apoptosis via decrease of XIAP and p53 mediated increase of DR5 ... Furthermore, triptolide increased DR5 levels in OCI-AML3, while the DR5 increase was blunted in p53-knockdown OCI-AML3 and p53 mutated U937 cells, confirming a role for p53 in the regulation of DR5 ... In support of this finding, disruption of MDM2-p53 binding with subsequent increase in p53 levels by nutlin3a increased DR5 levels and sensitized OCI-AML3 cells to TRAIL
Maduro et al., Int J Radiat Oncol Biol Phys 2008 (Uterine Cervical Neoplasms) : p53 suppression, as well as small interfering RNA against DR5, resulted in a significant downregulation of DR5 membrane expression but did not affect apoptosis induced by irradiation and rhTRAIL ... Irradiation results in a p53 dependent increase in DR5 membrane expression
Wang et al., J Biol Chem 2009 (Carcinoma, Hepatocellular...) : Notch1 signaling sensitizes tumor necrosis factor related apoptosis inducing ligand induced apoptosis in human hepatocellular carcinoma cells by inhibiting Akt/Hdm2 mediated p53 degradation and up-regulating p53 dependent DR5 expression ... Furthermore, Notch1 signaling could enhance DR5 expression in a p53 dependent manner ... Taken together, Notch1 signaling sensitizes TRAIL induced apoptosis in HCC cells by inhibiting Akt/Hdm2 mediated p53 degradation and up-regulating p53 dependent DR5 expression
Hori et al., Cancer Lett 2010 (Colonic Neoplasms) : The expressions of DR4 and DR5, Tumor necrosis factor (TNF) related apoptosis inducing ligand ( TRAIL ) receptors, are regulated by p53
Duiker et al., Br J Cancer 2011 (Carcinoma...) : Cellular FLICE-inhibitory protein ( c-FLIP ) and p53 siRNA experiments showed that neither an altered caspase 8/c-FLIP ratio nor a p53 dependent increase in DR5 membrane expression following cisplatin were involved in rhTRAIL sensitisation
Kuribayashi et al., Cell cycle (Georgetown, Tex.) 2011 : DR5 , Fas, Bax, Bad, Puma and Bnip3L were induced by 5-FU and adriamycin ( ADR ) in HCT116 cells in a p53 dependent manner
Xiaowen et al., Mol Biol Rep 2012 (Prostatic Neoplasms) : Triptolide sensitizes TRAIL induced apoptosis in prostate cancer cells via p53 mediated DR5 up-regulation
Surget et al., Cancer Res 2012 (Chromosome Deletion...) : Cell death via DR5, but not DR4 , is regulated by p53 in myeloma cells ... Increase of lexatumumab efficiency induced by nutlin-3a was related to a p53 dependent increase of DR5 expression
Cheng et al., Cell cycle (Georgetown, Tex.) 2012 (Neoplasms) : Induction of DR4 and DR5 was independent of p53 , Bax and Bim but was dependent on c-Jun N terminal kinase (JNK) as JNK pharmacological inhibition and siRNA abolished the induction of the TRAIL receptors by MMC
Park et al., Anticancer Drugs 2013 (Kidney Neoplasms) : Nutlin-3, a small-molecule MDM2 inhibitor, sensitizes Caki cells to TRAIL induced apoptosis through p53 mediated PUMA upregulation and ROS mediated DR5 upregulation
Zeki et al., Int J Cancer 1998 (Thyroid Neoplasms) : Induction of expression of MHC-class-II antigen on human thyroid carcinoma by wild-type p53